We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
- Authors
Rinke, Anja; Müller, Hans-Helge; Schade-Brittinger, Carmen; Klose, Klaus-Jochen; Barth, Peter; Wied, Matthias; Mayer, Christina; Aminossadati, Behnaz; Pape, Ulrich-Frank; Bläker, Michael; Harder, Jan; Arnold, Christian; Gress, Thomas; Arnold, Rudolf; PROMID Study Group
- Abstract
Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate. We performed a placebo-controlled, double-blind, phase IIIB study in patients with well-differentiated metastatic midgut NETs. The hypothesis was that octreotide LAR prolongs time to tumor progression and survival.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 28, p4656
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.22.8510